CN1503633A - 包含散发异味的油的可摄入组合物 - Google Patents
包含散发异味的油的可摄入组合物 Download PDFInfo
- Publication number
- CN1503633A CN1503633A CNA028067533A CN02806753A CN1503633A CN 1503633 A CN1503633 A CN 1503633A CN A028067533 A CNA028067533 A CN A028067533A CN 02806753 A CN02806753 A CN 02806753A CN 1503633 A CN1503633 A CN 1503633A
- Authority
- CN
- China
- Prior art keywords
- oil
- surfactant
- capsule
- take
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- 239000003921 oil Substances 0.000 claims abstract description 71
- 235000019198 oils Nutrition 0.000 claims abstract description 70
- 239000002775 capsule Substances 0.000 claims abstract description 59
- 239000004094 surface-active agent Substances 0.000 claims abstract description 56
- 235000021323 fish oil Nutrition 0.000 claims abstract description 28
- 239000001885 petroselinum crispum mill. leaf oil Substances 0.000 claims abstract description 17
- 239000004615 ingredient Substances 0.000 claims abstract description 16
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940041616 menthol Drugs 0.000 claims abstract description 3
- 230000035943 smell Effects 0.000 claims description 76
- 230000002159 abnormal effect Effects 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 12
- -1 polyoxyethylene glycerol Polymers 0.000 claims description 10
- 239000002002 slurry Substances 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 claims description 2
- 240000001519 Verbena officinalis Species 0.000 claims description 2
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 claims description 2
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 claims description 2
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 206010015137 Eructation Diseases 0.000 abstract 1
- 240000006927 Foeniculum vulgare Species 0.000 abstract 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 abstract 1
- 244000062730 Melissa officinalis Species 0.000 abstract 1
- 235000010654 Melissa officinalis Nutrition 0.000 abstract 1
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 abstract 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 abstract 1
- 235000019477 peppermint oil Nutrition 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 16
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 13
- 229920000053 polysorbate 80 Polymers 0.000 description 13
- 229940068968 polysorbate 80 Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229940049964 oleate Drugs 0.000 description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 12
- 241000251468 Actinopterygii Species 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 9
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 239000000787 lecithin Substances 0.000 description 8
- 235000010445 lecithin Nutrition 0.000 description 8
- 229940067606 lecithin Drugs 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000004816 latex Substances 0.000 description 7
- 229920000126 latex Polymers 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- USDAQJSRGJCNNX-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;sulfuric acid Chemical compound OS(O)(=O)=O.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO USDAQJSRGJCNNX-JJKGCWMISA-N 0.000 description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 235000021324 borage oil Nutrition 0.000 description 5
- 229940059329 chondroitin sulfate Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000007887 hard shell capsule Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004407 iron oxides and hydroxides Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940069752 halibut liver oil Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Edible Oils And Fats (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seasonings (AREA)
Abstract
包装在一种软胶凝体或硬壳胶囊中的一种可摄入组合物,其包括一种类似鱼油的、可摄入的、散发异味的油,这种油能引起正在服用胶囊的人发生呼吸上的回流或嗳气等气味问题。减轻这种问题的方法是在可摄入组合物中至少包括一种表面活性剂,较佳方法是,使用重量比约为2%到约20%、且至少包含一种可食用的气味-掩盖成分,例如荷兰芹种子油、香蜂草、柠檬草油、茴香、薄荷油及薄荷醇。
Description
技术领域
本发明涉及至少包含一种可摄入的、散发异味的油(例如鱼油)的可摄入组合物,更具体而言,涉及被制造在软胶凝体或硬壳胶囊等胶囊中的此种可摄入组合物。
背景技术
WO-A-95/24893揭示了一种疏水药物的递送系统。疏水药物的生物利用度在活体中可以得到改善,其方法是使用一种包含一种可摄入的油和一种水平相对较高的、在药学上可接受的表面活性剂成分的药物载体系统,这种成分包括一种在活体中抑制油脂脂解的亲水表面活性剂成分,以及一种实质上能够减少亲水表面活性剂成分的脂解效应的亲脂性表面活性剂成分。此处揭示的可摄入油类并不具有那种通常被认为刺鼻的气味。
EP-A-0127297揭示了装入胶囊的维生素或矿物组合物,其中,尤其显著的情况是,溶解于油的维生素的生物利用度得到了改善,其方法是在组合物中加入重量比为30%到80%(较佳方法是,35%到75%)的一种聚氧化乙烯山梨醇酯,例如聚山梨醇酯80,其目的在于在胃肠道中形成一种油解维生素的微乳剂。该组合物可能进一步包括以一种醇形式出现的一种稀释剂,一种植物油或其中一种衍生物。因此,EP-A-0127297并不关注缓释类似鱼油的、散发异味的油在摄取后出现的嗳气问题。
WO98/42319揭示了本质上非水性的口服组合物,其包含一种在生物学方面具有活性的油或油溶解成分,例如油解维生素,经过使用一种HLB(疏水/亲脂平衡)值为10到18的乳化剂系统,这种成分可以在载体油中作为一中分散形式得以保持。该发明的目的与EP-A-0127297的目的类似,即通过使活性成分在服用之后在胃液中变成完全分散形式的方法来改良活性成分的生物利用度。此处揭示了鱼油类的使用,以及大量在生物学方面可能具有活性的油或油解成分的使用,但是没有提到与这种油类使用相关的嗳气问题。此处提到如何避免令人不快的味道,这一点被当作使用一种胶囊剂量形式相对于一种液态剂量形式而体现的优点。
US-A-6056971揭示了一种在胃肠道中提高相对不容易溶解于水的饮食补充物的分解性质的方法,特别是辅酶Q-10(泛醌)。该方法包括将一种非离子的表面活性剂与一种多元醇混合,以便形成一种统一的合剂,然后将其混入饮食补充物,以便形成一种非水性溶液,该溶液包含重量比约20%到90%的表面活性剂,以及重量比约2%到50%的多元醇。然后,该溶液能被包装进一种软胶凝体胶囊中。此处没有提到摄取类似鱼油的、散发异味的油类时发生的嗳气问题。
US-A-5900251揭示了一种用于治疗和控制呼吸气味和用于帮助消化的、本质上属于草药或草药萃取物的组合物,其包含被装入类似胶囊的一种可摄入递送系统的姜、甘草精、甘菊、荷兰芹种子油和葵花籽油。其中姜、甘草精和甘菊被用作较佳的草药或草药萃取消化辅助剂,而这些成分中没有一种通常被视为令人不快的气味。其中荷兰芹种子油被用作较佳的呼吸清洁成分,用来清洁呼吸中的气味,例如在胃及肠道其他部分中产生的食糜气味。葵花籽油被用作较佳的可摄入油的载体。该组合物更进一步包括一种乳化剂和一种悬浮剂。悬浮剂被用来在油载体中悬浮活性成分。典型情况下,乳化剂选自天然乳化剂、合成表面活性剂和固体粒子乳化剂。加入乳化剂的目的没有得到明确的揭示,尽管可以从第2栏第54到58行的内容中得出推论,认为该成分被用来和油载体和悬浮剂一起提供一种适当的递送手段,以便活性成分能被递送到胃或消化道低端,而不会在口腔、咽喉或食道中出现大量的释放。
GB2324457揭示了一种饮食补充物,其包含一种被用一种乳化剂乳化进水中的营养油,以便形成胶束化的小液滴。这种小液滴用一种类似植物寡糖的修正淀粉而被装入胶囊。这种修正淀粉涂层的作用在于保护油免受氧和紫外线光照射的降解。该淀粉涂层也能遮蔽油的口味、气味和质地。
WO89/02223关注的问题在于避免非氢化鱼油类口味在稳定乳胶液中(例如沙拉调味品)的降解。取得这种改善结果的方法是在食物产品中加入小量的果糖。一种油解口味遮蔽剂,例如柠檬油,也可能被包含在产品中。同样地,US4961939关注的问题在于避免形成来自包含鱼油的、油包水型或水包油型乳剂的恶臬醇和醛类,以便除去令人不快的气味和异味。
GB2349817揭示了一种软明胶胶囊,其胶囊内容加入了一种遮蔽剂,而且其胶囊壳本身也包含一种遮蔽剂。橘子油是一种遮蔽剂的例子。据说该产品能在吞咽期间改善味道,减少返回的后味觉并减少气味。
CA2293088关注的问题在于遮蔽,举例来说,在食物补充药物中的鱼油气味和味道,而不会引入一种较强的味道或气味。取得这种结果的方法是将准备遮蔽的鱼油和麝香草香精相混合。
包含类似鱼油的、散发异味的油的可摄入组合物具有特别的问题,即摄取不久后就容易出现嗳气(或回流)现象,导致摄取此种组合物的人在嘴里出现一种令人不愉快的味道,并在呼吸中出现一种非常令人不愉快的气味,而且即使当这种组合物被没有经过咀嚼地全部吞咽下去时,也会发生这种情况。
发明内容
本发明的目标之一在于提供一种经过改良的可摄入组合物,以便递送一种可摄入的、但是散发令人不快的异味的油,并减少摄取之后产生的气味。
本发明提供一种用于递送散发异味的油且能减少摄取之后产生的气味的胶囊,所述的胶囊包含一种实质上非水性的可摄入组合物,其至少包含一种可摄入的、散发异味的油,至少一种可食用的气味-掩盖成分,和至少一种可食用的表面活性剂。
本发明进一步提供在一种实质上非水性可摄入组合物中使用一种由至少一种可食用气味-掩盖成分和至少一种可食用表面活性剂组成的组合剂的方法,该组合物包含至少一种可摄入的、散发异味的油,以便减少摄取所述的至少一种可摄入的、散发异味的油之后产生的气味。
本发明也提供减少实质上非水性口服吸收组合物在摄取之后所产生的气味的方法,该组合物至少包含一种散发异味的油,其在所述的口服吸收组合物中包含至少一种可食用的气味-掩盖成分和至少一种可食用的表面活性剂。
可摄入组合物在较佳方法中是一种连续相位,是实质上非水性的系统。该组合物可能以乳胶浓缩液或糊状形式出现。
所述的至少一种可食用表面活性剂以有效数量出现,在摄取时,它的效果足以将所述的至少一种可摄入的、散发异味的油限定在胃中的乳状液中。较佳方法是,所述的至少一种可食用表面活性剂的使用范围在可摄入组合物总重量的约2%到约20%之内,较佳方法是,接近该范围的下端,举例来说,重量比约2%到约10%,约2%到约7%,或约5%到约7%。通过使用相对低水平的所述至少一种可食用表面活性剂,我们发现在摄取时,在胃中形成了一种相对粗糙的可摄入的、散发异味的油的乳胶液,这种乳胶液与所述的至少一种气味-掩盖成分相组合,能够实质上减少嗳气之后产生的味道和气味问题。在胃里形成的粗糙乳胶液将所述的至少一种可摄入的、散发异味的油限定成粗糙小液滴的形式,其表面具有表面活性剂,因此可以减少能够被释放的、散发异味的油的数量。所述的至少一种可食用气味-掩盖成分也受到限定,但是其碎片能剩余在胃的水性部分中,因此更为有效。
先前已经提到,在真正可摄入的组合物中使用脂肪、水和非常小量的表面活性剂(总组合物的约0.4%)可以通过可摄入的、散发异味的油的乳化作用来生产一种二相位合剂,以便在胶囊中使用。通过如此的一种组合物,在胃中只发生脂肪和油基体相对较慢的解离,因此导致气味释放的速度也减慢。然而,它也意味着油的消化也会变得缓慢。
依照本发明,所述的至少一种可食用表面活性剂出现在可摄入组合物中,这一点允许可摄入的、散发异味的油立刻得到分散,或当可摄入的组合物被包在一种胶囊里时,在胶囊溶解时可以立即分散。
所述的至少一种可食用表面活性剂可以从由亲水表面活性剂、亲脂表面活性剂和相关合剂组成的群体中进行选择。较佳方法是,所述的至少一种可食用表面活性剂是至少一种亲水表面活性剂和至少一种亲脂表面活性剂的一种合剂。
所述的至少一种亲水表面活性剂和所述的至少一种亲脂表面活性剂的重量比处于约1∶1.5到约1∶2.5的范围中,通常在约1∶2.1到约1∶1.7的范围中。
适当的亲水表面活性剂包括,但是不限于,具有C10到C18的脂肪酸的聚氧化乙烯甘油脂。较佳方法是,所述的至少一种亲水表面活性剂从由聚氧化乙烯山梨醇单油酸盐,聚氧化乙烯氢化蓖麻油和相关的组合所组成的群体中进行选择。更具体而言,所述的至少一种亲水表面活性剂可能从注册商标为聚山梨醇酯80BPC的聚氧化乙烯山梨醇单油酸盐,聚氧化乙烯(40)氢化蓖麻油类(例如注册商标为CremophorRH40的商业产品),以及相关组合所组成的群体中进行选择。
适当的亲脂表面活性剂包括,但不限于,具有C5到C10脂肪酸的甘油脂。举例来说,所述的至少一种亲脂表面活性剂可以从由山梨醇单油酸盐,甘油基单辛酸盐,甘油基双辛酸盐,甘油基单癸酸盐,甘油基双癸酸盐和其中任何两个或多个成分组合所组成的群体中进行选择。更具体而言,所述的至少一种亲脂表面活性剂可以从注册商标为Imwitor 988的商业制备产品,注册商标为Imwitor 742的商业制备产品,注册商标为Capmul MCM的商业制备产品,和其中任何两个或多个成分的组合而组成的群体中进行选择。
所述的至少一种可摄入的、散发异味的油可以从由鱼油,散发异味的植物油,其他在摄取该组合物的人的呼吸中产生令人不快的气味的可摄入的油类,以及其中任何两个或多个成分的组合所组成的群体中进行选择。这些油类的例子包括鱼肝油、鲨鱼肝油、大比目鱼肝油、来自多个鱼种的鱼油,以及鱼油浓缩液(例如以注册商标EPAX供应的产品)。
所述的至少一种可摄入的、散发异味的油的数量以组合物总重量为基础的重量比可能在约75%到约98%之间,较佳方法是在约85%到约98%之间。然而,所述至少一种可摄入的、散发异味的油的所述数量可能非常低(例如,低到30%),举例来说,在复合维生素剂或其他包含相对高水平的无机盐及其他的非油类物质的补充剂中。
合适的可食用气味遮蔽成分包括,但是不限于,气味-掩盖油类。举例来说,所述的至少一种气味遮蔽成分可以从荷兰芹种子油,蜜蜂花、柠檬草油、茴香、薄荷油、薄荷醇和其中任何两个或多个成分的组合组成的群体中进行选择。
所述的至少一种可食用气味-掩盖成分的用量效力应足以至少部分地遮蔽所述的至少一种可摄入的、散发异味的油的气味。根据所用的气味-掩盖成分的性质和散发异味的油的性质,气味-掩盖成分的用量基于所述的至少一种可摄入的、散发异味的油的总重量的重量比可能在约0.01%到约5%之间。
本发明的可摄入组合物可以通过在室温下简单地混合各种成分而制备。然而,当表面活性剂是一种亲脂和亲水表面活性剂的混合物时,正常情况下,亲脂表面活性剂将首先加入,而且在添加亲水表面活性剂之前应使混合物得到均质化处理。
可摄入组合物可以被封装在软胶凝体或硬壳胶囊中。软胶凝体封包方法的揭示见Lachman & Leibennann发表的第二版《工业药房理论与实务》中,伦敦Henry Kimpton出版社出版。硬壳胶囊填充液体的封包方法的揭示见《硬壳胶囊——发展和技术》,K.Ridgeway编,药学出版社出版,1987。在此引用该专利揭示,以作参考。
具体实施方式
在下列各项例子中,本发明将得到进一步的详细描述:
实施例1
按照下列各项重量比混合下列各项成分,以制定一种可摄入组合物:-
1.22 荷兰芹种子油(气味遮蔽成分)
25.0 山梨醇单油酸盐BP(亲脂表面活性剂)
12.2 聚山梨醇酯80BP(亲水表面活性剂)
0.02 胆钙化醇D3C(油性)BP/EP(维生素D)
0.26 DL阿尔发生育酚醋酸盐USP(维生素E)
1.02 合成维生素A浓缩剂BP/EP,1M iu/g
480 鳕鱼肝油(海洋黄金CLO PC0224)
使用标准软胶凝体胶囊制造技术,上述组合物被装入用明胶基形成的明胶胶囊,其包含下列各项成分:
200甘油BP/EP/USP
366纯水BP/EP/USP
434明胶,150Bloom EP
每个胶囊包含了520毫克可摄入组合物。
实施例2
重复实施例1以便制备每个包含1040毫克可摄入组合物的胶囊,
使用实施例1和2的胶囊进行下列各项试验:
1.一种实施例2的胶囊(选择1040mg尺寸以便可能产生最大的效果)给受检者咽下,该受检者报告在摄取2小时内没有嗳气发生。相比而言,相同的受检者报告,没有表面活性剂和荷兰芹系统的胶囊在10-15分钟内会产生嗳气。
2.受检者咀嚼实施例1的一种胶囊,使它在嘴中破裂。受检者报告,在感觉到荷兰芹种子油之前,先感觉到一种轻微的、类似鱼的味道,但这是唯一可以注意到的鱼类味道。甚至是在5分钟以后,受检者报告没有明显的残余鱼类味道。
对比而言,如果受检者咀嚼包含鱼油的传统胶囊使它在嘴中破裂,其没有任何表面活性剂或气味-掩盖成分,味道极其令人反感,以至于一些受检者发生恶心反应,且大部分人报告,味道将持续10分钟或更长的时间。
3.实施例2的一种胶囊的内容被挤进大约包含15ml自来水的小瓶子之内,然后加盖。一种单一的倒置形成了一种粗糙的乳胶液,但在闻小瓶子的内容时,没有发现鱼的气味,只有气味-掩盖原料,荷兰芹种子油的气味。乳胶液小液滴经过一段时间确实会合并,但是不象油类填充的胶囊那样形成完全的分层。甚至在数个小时之后,小瓶子里也没有出现气味。
实施例3(复合维生素制备)
通过混合下表所列的成分制备一种可摄入组合物。该表同时给出重量比和百分比。除非另有说明,否则个别成分具有与上文实施例1所列的相同的来源及/或等级。
材料 | 毫克/胶囊 | % |
碳酸钙BP/EP | 508.000 | 40.54 |
琉璃苣油 | 26.830 | 2.14 |
延胡索酸铁 | 21.980 | 1.75 |
硫酸锌 | 20.700 | 1.65 |
卵磷脂 | 16.507 | 1.32 |
DL阿尔发生育酚醋酸盐 | 7.599 | 0.61 |
脂肪混合物 | 103.582 | 8.27 |
硫酸氨基葡糖(K盐) | 67.500 | 5.39 |
硫酸软骨素 | 55.550 | 4.43 |
脉膊油(七海洋公司) | 100.063 | 7.99. |
去维生素雪鱼肝油(七海洋公司) | 285.633 | 22.80 |
荷兰芹种子油 | 1.000 | .08 |
山梨聚糖单油酸盐BP | 18.000 | 1.44 |
聚山梨醇酯80BP | 9.000 | 0.72 |
贝它胡萝卜素30%悬浮液 | 6.974 | 0.56 |
高丽叁榨出物5∶1 | 2.000 | 0.16 |
姜榨出物3∶1 | 2.000 | 0.16 |
五水亚硒酸盐钠 | 0.0832 | 微量 |
总数 | 1253.0012 |
使用标准软胶凝体胶囊制造技术,上述组合物被填充进非明胶胶囊之内,该胶囊按照下列各项成分所指示的相对比例制造:
182.6 甘油BP/EP/USP
500 纯水BP/EP/USP
234.6 修正淀粉
75.9 角叉菜素
6.9 二磷酸钠
1.04 赤色氧化铁浆E172
4.96 黑色氧化铁浆E172
一位测试受检者只报告了二次轻微嗳气,一次发生在单一胶囊摄取15分钟后,第二次出现在大约15分钟之后。
实施例4到13
通过混合下表所列的成分制备一种可摄入组合物。不用将组合物包装进胶囊之内。
通过测试受检者摄取一定重量(给定毫克/胶囊等同机量)的、以所述混合形式出现的组合物(即油或浆状物)来进行测试。
实施例4
材料 | 毫克/胶囊等同计量 | % |
碳酸钙BP/EP | 508 | 40.97 |
琉璃苣油 | 26.832 | 2.16 |
延胡索酸铁 | 21.98 | 1.77 |
硫酸锌 | 20.7 | 1.67 |
卵磷脂 | 16.508 | 1.33 |
维生素E | 7.6 | .61 |
脂肪混合物 | 103.584 | 8.35 |
硫酸氨基葡糖(K盐) | 67.5 | 5.44 |
硫酸软骨素 | 55.552 | 4.48 |
脉膊油(七海洋公司) | 100.064 | 8.07 |
去维生素雪鱼肝油(七海洋公司) | 285.632 | 23.04 |
荷兰芹种子油 | 1 | 0.081 |
山梨聚糖单油酸盐BP | 12.52 | 1.0 |
聚山梨醇酯80BP | 12.52 | 1.0 |
总数 | 1239.968 |
生产的混合物是一种浆状物。测试受检者报告可辨别出鱼油,而且此组合物有一种令人不快的味道。
实施例5
材料 | 毫克/胶囊等同计量 | % |
碳酸钙BP/EP | 508 | 40.97 |
琉璃苣油 | 26.832 | 2.16 |
延胡索酸铁 | 21.98 | 1.77 |
硫酸锌 | 20.7 | 1.67 |
卵磷脂 | 16.508 | 1.33 |
维生素E | 7.6 | .61 |
脂肪混合物 | 103.584 | 8.35 |
硫酸氨基葡糖(K盐) | 67.5 | 5.44 |
硫酸软骨素 | 55.552 | 4.48 |
脉膊油 | 100.064 | 8.07 |
去维生素雪鱼肝油(七海洋公司) | 285.632 | 23.04 |
荷兰芹种子油 | 1 | 0.081 |
聚山梨醇酯80BP | 25.04 | 2.0 |
总数 | 1239.968 |
生产的混合物是一种浆状物。如同实施例4的情形一样,测试受检者报告可辨别出鱼油,而且此组合物有一种令人不快的味道。
实施例6
材料 | 毫克/胶囊等同计量 | % |
碳酸钙BP/EP | 508 | 39.70 |
琉璃苣油 | 26.832 | 2.1 |
延胡索酸铁 | 21.98 | 1.72 |
硫酸锌 | 20.7 | 1.62 |
卵磷脂 | 16.508 | 1.29 |
维生素E | 7.6 | 0.59 |
脂肪混合物 | 103.584 | 8.1 |
硫酸氨基葡糖(K盐) | 67.5 | 5.28 |
硫酸软骨素 | 55.552 | 4.34 |
脉膊油 | 100.064 | 7.82 |
去维生素雪鱼肝油(七海洋公司) | 285.632 | 22.32 |
荷兰芹种子油 | 1 | 0.078 |
聚山梨醇酯80BP | 64.52 | 5.04 |
总数 | 1279.448 |
生产的混合物是一种浆状物。测试受检者报告几乎无法辨别出鱼油,而且该气味被更强烈的荷兰芹种子油味所掩盖。
实施例7
材料 | 毫克/胶囊等同计量 | % |
碳酸钙BP/EP | 508 | 37.6 |
琉璃苣油 | 26.832 | 1.99 |
延胡索酸铁 | 21.98 | 1.63 |
硫酸锌 | 20.7 | 1.53 |
卵磷脂 | 16.508 | 1.22 |
维生素E | 7.6 | 0.56 |
脂肪混合物 | 103.584 | 7.67 |
硫酸氨基葡糖(K盐) | 67.5 | 5.00 |
硫酸软骨素 | 55.552 | 4.11 |
脉膊油(七海洋公司) | 100.064 | 7.41 |
去维生素雪鱼肝油(七海洋公司) | 285.632 | 21.14 |
荷兰芹种子油 | 1 | .074 |
聚山梨醇酯80BP | 136.24 | 10.08 |
总数 | 1351.168 |
生产的混合物是一种浆状物。测试受检者报告没有辨别出鱼油,但是荷兰芹种子油味比实施例6的味道更强烈。
实施例8
材料 | 毫克/胶囊等同计量 | % |
鱼油18/12(EPAX3000TG,Pronova) | 480 | 94.78 |
山梨聚糖单油酸盐BP | 16.81 | 333 |
聚山梨醇酯80BP | 8.42 | 1.66 |
荷兰芹种子油 | 1.22 | 0.24 |
总数 | 506.45 |
生产的混合物是单一连续非水性相位。测试受检者报告口腔中能辨别出少量鱼油味道。
实施例9
材料 | 毫克/胶囊等同计量 | % |
鱼油18/12(EPAX3000TG,Pronova) | 480 | 96.76 |
山梨聚糖单油酸盐BP | 9.9 | 2.00 |
聚山梨醇酯80BP | 4.95 | 1.0 |
荷兰芹种子油 | 1.22 | 0.25 |
总数 | 496.07 |
生产的混合物是单一连续非水性相位。测试受检者报告口腔中能辨别出鱼油味道。
实施例10和11
材料 | 毫克/胶囊等同计量 | %(实施例6) | %(实施例7) |
碳酸钙BP/EP | 677.112 | 52.72 | 52.68 |
雪鱼肝油 | 500 | 38.93 | 38.S9 |
山梨聚糖单油酸盐BP | 17.12 | 1.33 | 1.33 |
聚山梨醇酯80BP | 8.56 | 0.66 | 0.66 |
薄荷油(Givauden Roure) | 1(实施例7使用2) | 0.078 | 0.156 |
卵磷脂 | 10.996 | 0.856 | 0.856 |
蜂腊 | 54.383 | 4.23 | 4.23 |
维生素E | 15.2 | 1.18 | 1.18 |
总数实施例6 | 1284.371 |
实施例7 | 1285.371 |
|生产的混合物是浆状物。测试受检者报告能辨别出鱼油味道(实施例10),但是水平远远低于不使用山梨聚糖单油酸盐和聚山梨醇酯的对比实施例。薄荷味不显著。加倍薄荷油的水平(实施例11)能显著地改良味道,而且薄荷味开始使鱼油味道在口腔中淡化。
实施例12
材料 | 毫克/胶囊等同计量 | % |
碳酸钙BP/EP | 677.112 | 53.84 |
雪鱼肝油 | 500 | 39.75 |
山梨聚糖单油酸盐BP | 34.96 | 2.78 |
聚山梨醇酯80BP | 17.48 | 1.39 |
薄荷油(Givauden Roure) | 2 | 0.16 |
卵磷脂 | 10.996 | 0.875 |
蜂腊 | 54.383 | 4.32 |
维生素E | 15.2 | 1.2 |
总数 | 1257.748 |
生产的混合物是浆状物。测试受检者报告几乎不能辨别出鱼油味道,而且虽然不是特别地令人愉快的,也不确认鱼油是引发味道的因素。
实施例13
材料 | 毫克/胶囊等同计量 | % |
碳酸钙BP/EP | 677.112 | 50.53 |
雪鱼肝油 | 500 | 37.31 |
山梨聚糖单油酸盐BP | 53.52 | 3.99 |
聚山梨醇酯80BP | 26.76 | 2 |
薄荷油(Givauden Roure) | 2 | 0.149 |
卵磷脂 | 10.996 | 0.82 |
蜂腊 | 54.383 | 4.06 |
维生素E | 15.2 | 1.13 |
总数 | 1339.971 |
生产的混合物是浆状物。测试受检者报告混合物用一种含白垩的薄荷味道,没有辨别出鱼的味道。
Claims (21)
1.一种用来递送散发异味的油、且减少摄取之后的气味的胶囊,所述的胶囊包含一种实质上非水性的可摄入组合物,其包含至少一种可摄入的、散发异味的油,至少一种可食用气味-掩盖成分和至少一种可食用的表面活性剂。
2.根据权利要求1所述的胶囊,其中所述的可摄入组合物是连续相位。
3.根据权利要求1所述的胶囊,其中所述的可摄入组合物是浆状物。
4.根据上述任一权利要求所述的胶囊,其中所述的至少一种表面活性剂的用量范围在可摄入组合物总重量的约2%到约20%之间。
5.根据上述任一权利要求所述的胶囊,其中所述的至少一种表面活性剂的用量范围在可摄入组合物总重量的约2%到约10%之间。
6.根据上述任一权利要求所述的胶囊,其中所述的至少一种表面活性剂的用量范围在可摄入组合物总重量的约2%到约7%之间。
7.根据上述任一权利要求所述的胶囊,其中所述的至少一种表面活性剂的用量范围在可摄入组合物总重量的约5%到约7%之间。
8.根据上述任一权利要求所述的胶囊,其中所述的至少一种可食用气味-掩盖成分包括至少一种气味-掩盖油。
9.根据上述任一权利要求所述的胶囊,其中所述的至少一种气味-掩盖成分选自荷兰芹种子油、香蜂草、柠檬草油、茴香油、薄荷油、薄荷醇和其中任何两个或多个成分的组合中进行选择。
10.根据上述任一权利要求所述的胶囊,其中所述的至少一种可食用气味-掩盖成分的用量范围在可摄入的、散发异味的油的总重量的约0.01%到约5%之间。
11.根据上述任一权利要求所述的胶囊,其中所述的至少一种可食用表面活性剂选自亲水表面活性剂、亲脂表面活性剂和它们的混合剂。
12.根据权利要求11所述的胶囊,其中如使用亲水表面活性剂,则选自至少一种包含C10到C18脂肪酸的聚氧化乙烯甘油脂和聚氧化乙烯氢化蓖麻油及其组合的群体。
13.根据权利要求11所述的胶囊,其中如使用亲脂表面活性剂,则从一种或多种具备C5到C10脂肪酸的甘油酯中进行选择。
14.根据权利要求11到13任一项所述的胶囊,其中所述的至少一种表面活性剂是至少一种亲水表面活性剂和至少一种亲脂表面活性剂的混合物。
15.根据权利要求14所述的胶囊,其中所述的至少一种亲水表面活性剂与所述的至少一种亲脂表面活性剂的重量比例在约1∶1.5到约1∶2.5的范围中。
16.根据权利要求15所述的胶囊,其中所述的至少一种亲水表面活性剂与所述的至少一种亲脂表面活性剂的重量比例在约1∶1.7到约1∶2.1的范围中。
17.根据上述任一权利要求所述的胶囊,其中所述的至少一种可摄入的、散发异味的油的用量范围在可摄入组合物总重量的约75%到约98%之间。
18.根据上述任一权利要求所述的胶囊,其中所述的至少一种可摄入的、散发异味的油的用量范围在可摄入组合物总重量的约85%到约98%之间。
19.根据上述任一权利要求所述的胶囊,其中所述的至少一种可摄入的、散发异味的油选自一种鱼油和不同鱼油的混合物。
20.在实质上非水性的、包含至少一种可摄入的、散发异味的油的可摄入组合物中使用至少一种可食用气味-掩盖成分和至少一种可食用表面活性剂的组合,用以减少所述的至少一种散发异味的油在摄取之后产生的气味。
21.一种减少实质上非水性的、包含至少一种散发异味的油的口服可摄入组合物在摄取之后产生的气味的方法,包括在所述的口服可摄入组合物中包括至少一种可食用气味-掩盖成分和至少一种可食用表面活性剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0101198.0 | 2001-01-17 | ||
GBGB0101198.0A GB0101198D0 (en) | 2001-01-17 | 2001-01-17 | Ingestible compositions containing an odoriferous oil |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1503633A true CN1503633A (zh) | 2004-06-09 |
CN1241645C CN1241645C (zh) | 2006-02-15 |
Family
ID=9906973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028067533A Expired - Lifetime CN1241645C (zh) | 2001-01-17 | 2002-01-16 | 包含散发异味的油的可摄入组合物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9532585B2 (zh) |
EP (1) | EP1351585B1 (zh) |
JP (1) | JP4969763B2 (zh) |
KR (1) | KR100901518B1 (zh) |
CN (1) | CN1241645C (zh) |
AU (1) | AU2002219388B2 (zh) |
CA (1) | CA2434471C (zh) |
DK (1) | DK1351585T3 (zh) |
ES (1) | ES2537296T3 (zh) |
GB (1) | GB0101198D0 (zh) |
HK (1) | HK1055222A1 (zh) |
MX (1) | MXPA03006361A (zh) |
NO (1) | NO20034014D0 (zh) |
NZ (1) | NZ527079A (zh) |
WO (1) | WO2002056709A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106998744A (zh) * | 2014-12-15 | 2017-08-01 | 雀巢产品技术援助有限公司 | 咖啡因的控制释放 |
CN108208838A (zh) * | 2018-03-09 | 2018-06-29 | 北京素维生物科技有限公司 | 一种掩味组合物及其用途 |
TWI659748B (zh) * | 2013-03-22 | 2019-05-21 | 日商小林製藥股份有限公司 | Oral composition |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050037065A1 (en) * | 1999-05-27 | 2005-02-17 | Drugtech Corporation | Nutritional formulations |
FR2861261B1 (fr) * | 2003-10-22 | 2007-11-16 | Adisseo France Sas | Procede zootechnique pour l'administation d'un derive de vitamine e et formulation |
GB0601498D0 (en) | 2006-01-25 | 2006-03-08 | Probio Nutraceuticals As | Product |
JP5183104B2 (ja) * | 2006-06-19 | 2013-04-17 | 森下仁丹株式会社 | 口臭除去用多重ソフトカプセル |
WO2008101344A1 (en) * | 2007-02-22 | 2008-08-28 | Peter Tomlinson | Soluble bioactive lipophilic compounds compositions |
EP3187182B1 (en) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
DK2443246T3 (en) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
JP5951489B2 (ja) | 2009-10-16 | 2016-07-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 組成物 |
GB201006012D0 (en) * | 2010-04-09 | 2010-05-26 | Ayanda As | Composition |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) * | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
JP6042086B2 (ja) * | 2012-03-30 | 2016-12-14 | 小林製薬株式会社 | ゼラチン成形組成物 |
EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US11147841B2 (en) | 2014-12-19 | 2021-10-19 | Aker Biomarine Antarctic As | Enhanced omega-3 formulations |
US11337422B2 (en) * | 2015-04-17 | 2022-05-24 | Unm Rainforest Innovations | Non-toxic larvicide |
WO2016168837A1 (en) * | 2015-04-17 | 2016-10-20 | Stc.Unm | A novel non-toxic larvicide |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
JP6321100B2 (ja) * | 2016-09-07 | 2018-05-09 | 小林製薬株式会社 | ゼラチン成形組成物 |
TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
WO2019093708A1 (ko) * | 2017-11-08 | 2019-05-16 | 김승수 | 악취 억제형 불포화오일 및 아르기닌 함유 조성물의 제조 방법 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3721389A (en) * | 1971-06-10 | 1973-03-20 | Boeing Co | Exit nozzle assemblies for gas turbine power plants |
JPS55105623A (en) | 1979-02-08 | 1980-08-13 | Grelan Pharmaceut Co Ltd | Preparation of filler for hard capsules |
JPS5665820A (en) | 1979-11-02 | 1981-06-03 | Eisai Co Ltd | Hard capsule with high content of tocopherol nicotinate |
AU561367B2 (en) | 1983-05-02 | 1987-05-07 | Scherer, R.P. Pty. Ltd. | Vitamin composition with enhanced bioavailability |
JPS6115649A (ja) * | 1984-06-30 | 1986-01-23 | Asahi Denka Kogyo Kk | 油性食品 |
JPS6115647A (ja) | 1984-06-30 | 1986-01-23 | Asahi Denka Kogyo Kk | 油脂食品 |
CA1259966A (en) * | 1985-02-27 | 1989-09-26 | Taizo Yamamoto | Capsule filling apparatus |
DE3702031A1 (de) | 1987-01-24 | 1988-08-04 | Basf Ag | Verfahren zur herstellung von mikrodispersen fischoelpraeparaten |
US4853247A (en) * | 1987-06-16 | 1989-08-01 | Warner-Lambert Co. | Taste and odor masked edible oil compositions |
US4913921A (en) * | 1987-09-11 | 1990-04-03 | General Mills, Inc. | Food products containing fish oils stabilized with fructose |
US4961939A (en) * | 1989-06-02 | 1990-10-09 | Nabisco Brands, Inc. | Deodorized water-in-oil emulsion containing fish oil |
DK0487575T3 (da) | 1989-08-17 | 1994-11-28 | Cortecs Ltd | Farmaceutiske formuleringer |
JPH03130042A (ja) | 1989-10-17 | 1991-06-03 | Nippon Oil & Fats Co Ltd | 高度不飽和脂肪酸含有油脂の臭気マスキング方法 |
JPH06505959A (ja) * | 1990-05-07 | 1994-07-07 | ボッコー バリー アイ | 安定な脱臭油及びその医薬組成物の方法及び製剤 |
JPH0668A (ja) * | 1992-06-18 | 1994-01-11 | Sanwa Kagaku Kenkyusho Co Ltd | 海産動物性油脂濃縮物含有組成物及び該組成物を含有する食品 |
JPH06133707A (ja) * | 1992-10-23 | 1994-05-17 | Chugai Pharmaceut Co Ltd | 多価不飽和脂肪酸含有油脂組成物の香味改善法およびその利用食品 |
JP3534199B2 (ja) | 1993-11-10 | 2004-06-07 | 株式会社薬研 | 界面活性剤組成物 |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5603951A (en) * | 1994-11-09 | 1997-02-18 | Hanmi Pharm. Ind. Co., Ltd. | Cyclosporin-containing soft capsule compositions |
JPH09132775A (ja) * | 1995-02-13 | 1997-05-20 | Kiteii:Kk | 油状生理活性物質の安定化剤 |
US5853761A (en) * | 1995-02-13 | 1998-12-29 | Fujisawa Pharmaceutical Co., Ltd. | Stabilizing agent for oleaginous, physiologically active substances |
JPH0984557A (ja) * | 1995-09-20 | 1997-03-31 | Morimitsu Miyagi | 合成肝油の製造物 |
US5900251A (en) * | 1996-06-10 | 1999-05-04 | Breath Asure, Inc. | Internal breath freshener and digestive aid |
US6056971A (en) * | 1996-07-24 | 2000-05-02 | Biosytes Usa, Inc. | Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same |
US5702231A (en) * | 1996-08-09 | 1997-12-30 | The Boeing Company | Apparatus and method for reducing noise emissions from a gas turbine engine inlet |
JPH10251143A (ja) * | 1997-03-10 | 1998-09-22 | Sansei Iyaku Kk | ソフトカプセル |
GB9705813D0 (en) * | 1997-03-20 | 1997-05-07 | Smithkline Beecham Plc | Novel compositions |
GB2324457B (en) | 1997-04-26 | 2001-05-30 | Cultech Ltd | Nutritional supplement |
US6112514A (en) * | 1997-11-05 | 2000-09-05 | Virginia Tech Intellectual Properties, Inc. | Fan noise reduction from turbofan engines using adaptive Herschel-Quincke tubes |
JP4761093B2 (ja) * | 1997-12-10 | 2011-08-31 | シクロスポリン セラポイティクス リミテッド | オメガ−3脂肪酸油を含む医薬組成物 |
DE19854987B4 (de) | 1998-11-27 | 2005-12-08 | Josef Schwarzkopf | Mischung zur Reduzierung von Speisegerüchen |
CA2293088A1 (en) | 1998-12-28 | 2000-06-28 | Lionel Leroy Quinlan | Method and composition for masking taste and odor from fish oil |
GB2349817A (en) * | 1999-03-12 | 2000-11-15 | K T Lalvani | uSE OF MASKING AGENTS WITH CAPSULES |
US6346231B1 (en) * | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
JP2001131575A (ja) | 1999-11-05 | 2001-05-15 | Nof Corp | 臭気がマスクされた水産動物油脂 |
-
2001
- 2001-01-17 GB GBGB0101198.0A patent/GB0101198D0/en not_active Ceased
-
2002
- 2002-01-16 KR KR1020037009588A patent/KR100901518B1/ko active IP Right Grant
- 2002-01-16 DK DK02732094.4T patent/DK1351585T3/en active
- 2002-01-16 AU AU2002219388A patent/AU2002219388B2/en not_active Expired
- 2002-01-16 WO PCT/GB2002/000164 patent/WO2002056709A1/en active IP Right Grant
- 2002-01-16 ES ES02732094.4T patent/ES2537296T3/es not_active Expired - Lifetime
- 2002-01-16 CA CA2434471A patent/CA2434471C/en not_active Expired - Lifetime
- 2002-01-16 JP JP2002557225A patent/JP4969763B2/ja not_active Expired - Lifetime
- 2002-01-16 EP EP02732094.4A patent/EP1351585B1/en not_active Expired - Lifetime
- 2002-01-16 NZ NZ527079A patent/NZ527079A/en not_active IP Right Cessation
- 2002-01-16 CN CNB028067533A patent/CN1241645C/zh not_active Expired - Lifetime
- 2002-01-16 MX MXPA03006361A patent/MXPA03006361A/es active IP Right Grant
- 2002-01-16 US US10/466,896 patent/US9532585B2/en not_active Expired - Lifetime
-
2003
- 2003-09-11 NO NO20034014A patent/NO20034014D0/no unknown
- 2003-10-16 HK HK03107511.2A patent/HK1055222A1/zh not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI659748B (zh) * | 2013-03-22 | 2019-05-21 | 日商小林製藥股份有限公司 | Oral composition |
CN106998744A (zh) * | 2014-12-15 | 2017-08-01 | 雀巢产品技术援助有限公司 | 咖啡因的控制释放 |
US11096897B2 (en) | 2014-12-15 | 2021-08-24 | Societe Des Produits Nestle S.A. | Controlled release of caffeine |
CN108208838A (zh) * | 2018-03-09 | 2018-06-29 | 北京素维生物科技有限公司 | 一种掩味组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
KR100901518B1 (ko) | 2009-06-08 |
NZ527079A (en) | 2005-09-30 |
GB0101198D0 (en) | 2001-02-28 |
EP1351585A1 (en) | 2003-10-15 |
US20040121000A1 (en) | 2004-06-24 |
HK1055222A1 (zh) | 2004-01-02 |
DK1351585T3 (en) | 2015-07-06 |
ES2537296T3 (es) | 2015-06-05 |
NO20034014L (no) | 2003-09-11 |
US9532585B2 (en) | 2017-01-03 |
JP2004520355A (ja) | 2004-07-08 |
AU2002219388B2 (en) | 2008-06-05 |
CN1241645C (zh) | 2006-02-15 |
CA2434471A1 (en) | 2002-07-25 |
KR20030093198A (ko) | 2003-12-06 |
WO2002056709A1 (en) | 2002-07-25 |
NO20034014D0 (no) | 2003-09-11 |
EP1351585B1 (en) | 2015-04-08 |
MXPA03006361A (es) | 2003-10-06 |
JP4969763B2 (ja) | 2012-07-04 |
CA2434471C (en) | 2011-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1241645C (zh) | 包含散发异味的油的可摄入组合物 | |
AU2002219388A1 (en) | Ingestible compositions containing an odoriferous oil | |
EP1782807B1 (en) | Jelly composition | |
CN101022786B (zh) | 用自乳化制剂释放亲脂性辅酶Q10(CoQ10)及其他膳食组分 | |
CN1142724C (zh) | 两阶段制剂 | |
US5900251A (en) | Internal breath freshener and digestive aid | |
MXPA05012050A (es) | Complemento dietetico y metodo para el tratamiento y prevencion de ulceras del tracto digestivo en equinos y otros animales. | |
TWI659748B (zh) | Oral composition | |
US20100261785A1 (en) | Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s) | |
US20120141446A1 (en) | Oral Nutritional Supplement Delivery System | |
WO1998018346A2 (de) | Geschmacksneutrale mikrokapseln, verfahren zu ihrer herstellung sowie ihre verwendung | |
CN1774179A (zh) | 供孕妇用的多种维生素及矿物质补充品 | |
WO2001084963A1 (fr) | Composition comestible comprenant de la poudre de nacre micronisee | |
JP2010227034A (ja) | 健康補助食品 | |
RU2419446C1 (ru) | Состав экстракта хвои густого для капсулирования | |
JP4262057B2 (ja) | 脂溶性有効成分配合食品 | |
WO2010064882A1 (ru) | Состав экстракта хвои густого для капсулирования | |
JP2001046017A (ja) | 健康食品組成物 | |
KR102486088B1 (ko) | 생체흡수율과 유화안정성 및 산패율이 개선된 오메가-3 스무디 제형 | |
CN1170541C (zh) | 苯并噁嗪酮类hiv逆转录酶抑制剂的口服液制剂 | |
JP4895422B2 (ja) | 呼気清涼化剤 | |
JP2022160699A (ja) | オリーブオイルをペットフード用の香料として生産し使用する方法 | |
JP2003063970A (ja) | 抗骨粗鬆症組成物 | |
JP2010077095A (ja) | ビタミンe含有ソフトカプセル | |
CN1143458A (zh) | 一种植物油脂组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SCHERER TECHNOLOGIES INC. R. P. Free format text: FORMER NAME: R.P SCHERER TECHNOLOGIES INC. |
|
CP03 | Change of name, title or address |
Address after: Carson City, Nevada, USA Patentee after: Scherer Technologies Inc. R. P. Address before: Nevada Patentee before: R.P Scherer Technologies Inc. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060215 |
|
CX01 | Expiry of patent term |